Clinical Practice, Industry News, Patient Care

Galderma Receives Approval for Restylane Shaype in Canada

February 14, 2024
Galderma, est. 1981

Galderma announced that it has received approval from Health Canada for Restylane Shaype, a hyaluronic acid (HA) injectable designed for temporary augmentation of the chin region. It is engineered to build and shape on bone with deep injection for a bone-mimicking effect.

The chin is a critical component of overall appearance that influences the balance of facial proportions, profile and shape. Genetics and age can impact overall chin definition, which may cause the appearance of a double chin. For decades, there has been a heavy reliance on implants to create structure in the lower face, with no non-surgical options available offering qualities close to an implant, per Galderma.

Read more at MedEsthetics >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Growth, Capital and Control: Navigating Private Equity in Aesthetics
    • Med Spas Under the Microscope – The View From The FDA
    • Revance and Teoxane Announce RHA Dynamic Volume is Now Available
    • Terri Ross Consulting Appoints Cameron Hemphill as Chief Operating Officer and Strategic Advisor
    • Galderma’s Restylane Contour Gains FDA Approval for the Correction of Temple Hollowing